SATURDAY September 23rd The Pain of Pleasure: Heroin and Other Opiods- The Implications for Oncology Practice: A Clinical Dilemma (Merrill Norton PharmD, DPh, ICCDP-D, University of Georgia College of Pharmacy) Checkpoint Blockade Toxicities: Horses and Zebras (Sapna P Patel MD,Department … Continued
Last weekend Dr. Chuck Jackson of Overall Ovations lead SUMO’s 2017 Board Retreat. We are feeling confident about the year to come and can’t wait to help Utah’s oncology staff care for their patients. Click Here for pictures of the … Continued
U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds … Continued
On September 22, 2017, the Food and Drug Administration granted accelerated approval to nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib.